Latest News for: cutaneous

Edit

Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study For Early-Stage Cutaneous T-Cell Lymphoma Treatment

MENA FN 04 Apr 2025
(MENAFN - Investor Brand Network). Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. SNGX's HyBryte is a novel photodynamic therapy ... .
Edit

Cutaneous T-Cell Lymphoma (CTCL) Treatment Market 2034: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, ...

GetNews 28 Mar 2025
"Cutaneous T-Cell Lymphoma (CTCL) Treatment Market" ... Some facts of the Cutaneous T-Cell Lymphoma Market Report are. According to DelveInsight, Cutaneous T-Cell Lymphoma Market is expected to grow at a decent CAGR by 2034.
  • 1
×